Arca
Skip to content
Tools
Tools

Stroke

Drug research and approvals for stroke: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 1,698 studies of stroke are recruiting on ClinicalTrials.gov, Health Canada has authorized 49 drug trials for it since 2013, FDA has 0 approved and 8 open orphan designations naming it, and the EU has 17 authorised medicines for it.

  • Recruiting worldwide: 1,698
  • Trials authorized in Canada: 49
  • FDA orphan approvals: 0
  • EU medicines: 17

Recruiting Now

Newest start dates first, of 1,698 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

37 approved, 47 in phase 3, 56 in phase 2, 16 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Alteplase, Aspirin, Warfarin, Clopidogrel, Apixaban, Rivaroxaban, Ticagrelor, Edoxaban, Dipyridamole, Atorvastatin, Simvastatin, Candesartan cilexetil, Lisinopril anhydrous, Propranolol, Telmisartan, Valsartan, Dabigatran etexilate, Nebivolol, Aliskiren, Atenolol, Azilsartan medoxomil, Benazepril, Celecoxib, Dantrolene, Losartan, Metoprolol, Nadolol, Olmesartan medoxomil, Quinapril, Ramipril, Vorapaxar, Ticlopidine, Torsemide, Sitagliptin, Eplerenone, Amlodipine, Evolocumab

Tenecteplase
Phase 3 Tissue-type plasminogen activator exogenous protein
Onabotulinumtoxina
Phase 3 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
Abciximab
Phase 3 Integrin alpha-IIb/beta-3 inhibitor
Desmoteplase
Phase 3 Plasminogen activator
Fluoxetine
Phase 3 Serotonin transporter inhibitor
Levodopa
Phase 3 Dopamine D3 receptor agonist
Urokinase
Phase 3 Urokinase-type plasminogen activator exogenous protein
Carbidopa anhydrous
Phase 3 DOPA decarboxylase inhibitor
Rosuvastatin
Phase 3 HMG-CoA reductase inhibitor
Dabigatran
Phase 3 Thrombin inhibitor
Nerinetide
Phase 3
Citalopram
Phase 3 Serotonin transporter inhibitor
Hydroxyurea
Phase 3 Ribonucleoside-diphosphate reductase RR1 inhibitor
Nitroglycerin
Phase 3 Soluble guanylate cyclase activator
Lidocaine
Phase 3 Sodium channel alpha subunit blocker
Heparin
Phase 3 Antithrombin-III activator
Donepezil
Phase 3 Acetylcholinesterase inhibitor
Incobotulinumtoxina
Phase 3 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
Lithium carbonate
Phase 3 Inositol-1(or 4)-monophosphatase 1 inhibitor
Norepinephrine
Phase 3 Adrenergic receptor agonist
Remifentanil
Phase 3 Mu opioid receptor agonist
Dalteparin sodium
Phase 3 Antithrombin-III activator
Estrogens, conjugated
Phase 3 Estrogen receptor agonist
Suxamethonium
Phase 3 Muscle-type nicotinic acetylcholine receptor agonist
Imatinib
Phase 3 Tyrosine-protein kinase ABL inhibitor
Modafinil
Phase 3 Dopamine transporter inhibitor
Phenylephrine
Phase 3 Adrenergic receptor alpha-1 agonist
Clevidipine
Phase 3 Voltage-gated L-type calcium channel blocker
Propofol
Phase 3 GABA-A receptor; anion channel positive allosteric modulator
Etomidate
Phase 3 GABA-A receptor; anion channel positive modulator

Showing the 30 furthest along of 119 in trials.

How Its Trials Ended

6,163 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 976 whose ending is known, 42% met their primary endpoint, 11% missed it and 47% stopped early.

  • Completed, result not reported2,51641%
  • Ongoing1,63827%
  • Status unknown1,03317%
  • Met its primary endpoint4137%
  • Stopped: other or unclear2825%
  • Missed its primary endpoint1052%
  • Stopped: enrollment or feasibility1002%
  • Stopped: lack of efficacy270%
  • Stopped: funding240%
  • Stopped: sponsor or business decision190%
  • Stopped: safety60%

Trials Authorized in Canada

The 10 newest of 49; search them all in Canada trials
Sep 25, 2026A phase 2a multicenter, randomized, double-blind, placebo-controlled, parallel-arm domain within the act-global trial platform, to evaluate the dose-response,…NTS-521Neurotrauma Sciences, LLCOngoing
Sep 10, 2026A phase 3, randomized, multicenter, double-blind study to assess stroke and systemic embolism prevention with regn7508, a monoclonal antibody against factor…REGN7508 / eliquisRegeneronOngoing
Jul 10, 2026Safety and efficacy of intravenous thrombolysis in patients with ischemic stroke on treatment with direct oral anticoagulants: do-it – the doac intravenous…Tnkase / activaseInsel Gruppe AG, Inselspital (University Hospital) BernPending
Nov 6, 2025Glucagon-like peptide-1 receptor agonists for endovascular stroke thrombectomyOzempic / apo-semaglutide injectionHamilton Health Sciences CorporationPending
Jan 24, 2025Optimizing reperfusion to improve outcomes and neurologic function (orion): a multicenter, double-blind, placebo controlled, randomized, parallel-group, phase…JX10Corxel Pharmaceuticals, Co, LtdOngoing
Nov 1, 2024Phase 2/3 adaptive design, randomized double-blind placebo-controlled study to evaluate the safety and efficacy of dm199 for the treatment of acute ischemic…DM199 (rinvecalinase alfa)Diamedica IncOngoing
Oct 1, 2024A multicenter, double-blinded, placebo-controlled, single ascending dose, twopart, randomized, phase 2 clinical trial to assess safety, tolerability,…BB-031Basking Biosciences, IncOngoing
Aug 15, 2024An investigator-initiated phase 3 multicentre open-label blinded-endpoint randomized controlled trial to evaluate the efficacy and safety of very low-dose…EdoxabanSunnybrook Research InstitutePending
May 14, 2024Nuance-icad: effect of genotype-guided oral p2y12 inhibitor selection vs conventional clopidogrel therapy in symptomatic intracranial atherosclerotic disease:…TicagrelorSunnybrook Research InstituteOngoing
Mar 7, 2024Thrombolysis domain (act when) a multi-factorial, multi-arm, multi-stage, randomised, global adaptive platform trial for stroke (act-global)TnkaseGovernors Of The University Of Calgary/Dr. Bijoy MenonOngoing

FDA Orphan Designations

Approved first, then open designations, newest first
Aug 27, 2026TaurineTreatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS)Kalevala Therapeutics, Inc.Designated
Oct 14, 2024GlyburideTreatment of large territory acute ischemic strokeRemedy Pharmaceuticals, Inc.Designated
Apr 22, 2019MelatoninTreatment of heat strokeWORPHMED SrlDesignated
Jan 25, 2017Nicotinamide ribosideTreatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome (MELAS)Rejuvenation TherapeuticsDesignated
Jan 12, 2017GlyburideTreatment of severe cerebral edema in patients with acute ischemic strokeRemedy Pharmaceuticals, Inc.Designated
Apr 11, 2014H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Se…Treatment of acute ischemic stroke patients presenting within 3 hours of symptom onsetNoNO, Inc.Designated
Sep 25, 2012Dantrolene sodiumTreatment of heat strokeEagle Pharmaceuticals, Inc.Designated
Apr 18, 2011Tissue Plasminogen activatorTreatment of acute ischemic stroke (AIS) in children age 16 years and younger.Catherine Amlie-Lefond, MDDesignated

Medicines Authorised in the EU

Newest first; 15 of 17
Jul 23, 2020Apixaban AccordApixaban · genericAccord Healthcare S.L.U.EMA ↗
Apr 19, 2017RoteasEdoxabanBerlin-Chemie AGEMA ↗
Jun 19, 2015LixianaEdoxabanDaiichi Sankyo Europe GmbHEMA ↗
Feb 18, 2015Clopidogrel ratiopharmClopidogrel · genericTeva B.V.EMA ↗
Oct 28, 2010Clopidogrel HCSClopidogrel · genericHCS bvbaEMA ↗
Oct 16, 2009Clopidogrel Viatris (previously Clopidogrel Taw Pharma)Clopidogrel · genericViatris LimitedEMA ↗
Sep 28, 2009ZylltClopidogrel · genericKRKA tovarna zdravil d.d. Novo mestoEMA ↗
Sep 23, 2009Clopidogrel KrkaClopidogrel · genericKRKA tovarna zdravil d.d. Novo mestoEMA ↗
Sep 23, 2009Clopidogrel TADClopidogrel · genericTad Pharma GmbHEMA ↗
Sep 21, 2009Clopidogrel Taw Pharma (previously Clopidogrel Mylan)Clopidogrel · genericTaw Pharma (Ireland) LimitedEMA ↗
Sep 21, 2009Clopidogrel BGR (previously Zylagren)Clopidogrel · genericBiogaranEMA ↗
Sep 20, 2009Clopidogrel Krka d.d. (previously Zopya)Clopidogrel · genericNorpharm Regulatory Services LtdEMA ↗
Jul 27, 2009GrepidClopidogrel · genericPharmathen S.A.EMA ↗
Jul 27, 2009Clopidogrel Teva (hydrogen sulphate)Clopidogrel · genericTeva Pharma B.V.EMA ↗
Jul 15, 2008Clopidogrel Zentiva (previously Clopidogrel Winthrop)ClopidogrelZentiva k.s.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.